Our study found that the elevated MSLN in hepatic metastatic TNBC could activate the EGFR as well as downstream ERK1/2 signaling pathways, thereby promoting the ability of cancer cells to survive and proliferate in the liver, and further contributing to the formation of hepatic metastases. This evidence concerns the gene MAPK3 and cancer.